Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 14;13:959658. doi: 10.3389/fimmu.2022.959658

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Stenger, Giver, Langston, Kota, Das, Chinnadurai, Galipeau, Waller and Qayed

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Longitudinal immune profile following autologous MSC infusion. Flow cytometry was performed to evaluate lymphocyte subsets (CD3+CD4+ and CD3+CD8+; A, B), T-cell activation (CD69+; C, D), and regulatory T cells (E) longitudinally. Data (mean, SD) are shown by dose level, with timing of MSC infusion designated by arrows. The proportion of activated T cells was lowest at day 29 in dose level 3, although T-cell activation was higher at baseline in dose level 1. No significant differences were otherwise seen by dose level in T-cell counts or proportion of regulatory T cells. MSC, mesenchymal stromal cell; SD, standard deviation.